Does atovaquone provide effective prophylaxis for Pneumocystis pneumonia in children with leukemia?
Caryn G Morse and Joseph A Kovacs*
Correspondence *Critical Care Medicine Department, NIH Clinical Center, Room 2C145, Building 10, MSC 1662, 10 Center Drive, Bethesda, MD 20892–1662, USA
Email jkovacs@nih.gov
This article has no abstract so we have provided the first paragraph of the full text.
Prophylaxis for prevention of PCP is recommended as standard of care for patients with a diverse range of conditions including advanced HIV infection and many malignancies, as well as for patients undergoing HSCT or solid-organ transplant. Without effective chemoprophylaxis the incidence of PCP can be high in these populations. For example, PCP occurs in over 20% of patients with acute lymphoblastic leukemia,1 and can cause a mortality rate of nearly 60%.2 Over the past 20 years, however, the use of prophylaxis against P. jirovecii has substantially decreased the incidence of PCP in at-risk populations.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.